List of Excipients in Branded Drug ARMODAFINIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teva Pharmaceuticals USA Inc	ARMODAFINIL	armodafinil	0093-3090	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	ARMODAFINIL	armodafinil	0093-3090	CROSCARMELLOSE SODIUM
Teva Pharmaceuticals USA Inc	ARMODAFINIL	armodafinil	0093-3090	LACTOSE MONOHYDRATE

Generic Drugs Containing ARMODAFINIL

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	armodafinil	0378-3431	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	armodafinil	0378-3431	LACTOSE MONOHYDRATE
Mylan Pharmaceuticals Inc	armodafinil	0378-3431	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in ARMODAFINIL?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
2	CELLULOSE, MICROCRYSTALLINE
13	CROSCARMELLOSE SODIUM

Excipient Strategy and Commercial Opportunities for ARMODAFINIL

Last updated: March 1, 2026

What is the role of excipients in ARMODAFINIL formulations?

Excipients in ARMODAFINIL products serve multiple functions, including enhancing drug stability, improving bioavailability, facilitating manufacturing, and ensuring patient compliance. As a racemic mixture, ARMODAFINIL is sensitive to its formulation environment; hence, excipient selection is critical.

• Common excipients include diluents like microcrystalline cellulose, disintegrants such as croscarmellose sodium, binders like povidone, and surfactants such as sodium lauryl sulfate.
• Formulation variations impact bioavailability and stability, influencing patent strategies and generic entry.

How do excipient strategies influence formulation development?

Effective excipient choices can optimize ARMODAFINIL's pharmacokinetic profile, control manufacturing costs, and extend patent life.

• Extended-release formulations utilize hydrophilic polymers (e.g., hydroxypropyl methylcellulose) to prolong absorption.
• Immediate-release formulations benefit from fast-dissolving disintegrants, improving onset time.
• Excipient compatibility studies ensure stability under varied storage conditions, reducing risk of degradation.

What are the commercial implications of excipient selection?

Strategic excipient selection affects market positioning and regulatory approval:

• Patent protection: Formulation patents often hinge on unique excipient combinations and release mechanisms.
• Regulatory approval: Regulatory agencies require comprehensive data on excipient safety and compatibility.
• Market differentiation: Innovative excipient matrices can improve patient experience, providing a competitive advantage.

Opportunities in excipient innovation for ARMODAFINIL

Emerging trends and technological advancements create avenues for new product development:

• Solubilizing excipients: Enhance bioavailability for lower-dose formulations.
• Taste-masking agents: Improve palatability for pediatric or sensitive populations.
• Stability-enhancing excipients: Extend shelf life, especially in tropical climates.
• Biodegradable or plant-based excipients: Meet consumer demand for more natural or eco-friendly products.

Commercial success depends on aligning excipient strategies with clinical benefits, manufacturing feasibility, and regulatory pathways.

Market and patent landscape overview

The global ARMODAFINIL market, valued at approximately USD 4.2 billion in 2021, is expected to grow at a 7.2% CAGR through 2028 (Grandview Research). Key players include Cephalon (Teva), Sun Pharma, and Mylan.

Patent expirations are approaching for several formulations, opening opportunities for generics with optimized excipient profiles. Companies investing in innovation can potentially secure formulation patents, extending exclusivity and market share.

Conclusion

Excipient strategies for ARMODAFINIL influence formulation performance, regulatory compliance, and market competitiveness. Innovation in excipient selection offers opportunities to enhance bioavailability, stability, and patient acceptance, creating avenues for differentiation and value capture.

---

Key Takeaways

• Excipient selection is critical for optimizing ARMODAFINIL formulations and extending patent life.
• Formulation innovations, such as controlled-release systems and taste-masking, can provide competitive advantages.
• The market for ARMODAFINIL is expanding, with patent expirations prompting opportunities for new formulations with tailored excipients.
• Advances in excipient technology and sustainability trends present growth opportunities.

---

FAQs

What excipients are commonly used in ARMODAFINIL formulations?

Microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl sulfate, and hydroxypropyl methylcellulose are standard excipients.

How can excipients impact ARMODAFINIL’s bioavailability?

Excipient choice influences drug dissolution and absorption. Solubilizing agents increase bioavailability, while disintegrants promote rapid release.

Are there safety concerns related to excipients in ARMODAFINIL products?

Regulatory agencies require safety data for all excipients. Common excipients used are generally recognized as safe (GRAS) when within approved limits.

What formulation innovations are being explored for ARMODAFINIL?

Controlled-release systems, taste-masking formulations, and formulations with enhanced stability are under investigation.

How do patent strategies relate to excipient use?

Unique excipient combinations and release mechanisms can form the basis for formulation patents, providing market exclusivity.

---

References

[1] Grandview Research. (2022). Armodafinil market size, share & trends analysis. Retrieved from https://www.grandviewresearch.com/industry-analysis/armodafinil-market

[2] U.S. Food and Drug Administration. (2019). Guidance for Industry: Excipients in Approved Drug and Biological Products.

[3] World Health Organization. (2020). WHO Model List of Essential Medicines.